Impact of immunosuppressive therapy in IgA nephropathy

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00025167

Enrollment

150

Registered

2021-12-30

Start date

2020-11-04

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

N03.3

Interventions

Group 1: Immunosuppressive therapy with cyclophosphamide, which is given intravenously every four weeks for 3-6 months. We investigate kidney function as assessed by the serum creatinine, proteinuira,

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: Biopsy-proven IgA nephritis, therapy at the University Hospital of Freiburg between 2000 to 2020

Exclusion criteria

Exclusion criteria: systemic lupus erythematosus or Henoch-Schonlein Purpura

Design outcomes

Primary

Measure	Time frame
Kidney function after five years as assessed by the serum creatinine value.	—

Secondary

Measure	Time frame
proteinuria, hematuria	—

Countries

Germany

Contacts

Public ContactJohanna Schneider

Universitätsklinikum Freiburg, Medizin IV

johanna.schneider@uniklinik-freiburg.de0761-27032842

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026